Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AdventHealth
With
Mallinckrodt
Thrasher Research Fund
This is a single center, blinded, randomized control clinical trial to evaluate the effects of inhaled nitric oxide on the outcome of survival and incidence of bronchopulmonary dysplasia. This trial has a planned enrollment of 138 infants with 68 infants with delayed pulmonary transition assigned to either the treatment or placebo group. There is no enrollment restriction based on gender, ethnicity, or race. Enrollment is expected to take 36 months with an additional 12 months for data analysis.Infants with early pulmonary hypertension will be randomized to the treatment or placebo group. Treatment will continue until resolution of pulmonary hypertension or through Day 14, whichever comes first. Serial echocardiograms will be performed every 48 hours +/-12 hours until Day 14. Oxygen saturation levels will be averaged every 24 hour period following enrollment. This study will provide evidence for the beneficial effects of early diagnosis and treatment of pulmonary hypertension in preterm infants.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Step 1:
Birth between 23 weeks and 0 days and 29 weeks and 6 days.
Positive pressure ventilation at 72-96 hours of age
Step 2:
Early pulmonary hypertension
You may not be if
Step 1:
Death prior to 12 hours of age or first echocardiogram
Chromosomal anomalies
Major congenital anomalies
Myocardial dysfunction
Complex cardiac defect
Dependent on right to left shunting of blood
Step 2:
Excessive pulmonary blood flow (left to right shunt across PDA)
Pulmonary blood flow obstruction secondary to pulmonary vein stenosis